Title: Compositions and Methods for Inhibiting Expression of Eg5 Gene
Patent Number: 7,718,629
Filed: March 30, 2007
Lead Inventor: David Bumcrot, Alnylam Pharmaceuticals
"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the Eg5 gene comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene," the patent's abstract states. "The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition, and methods for inhibiting the expression of the Eg5 gene in a cell."
Title: Treatment Tool for Cancer: RNA Interference of BCAS2
Patent Number: 7,718,631
Filed: April 3, 2008
Lead Inventor: Show-Li Chen, National Taiwan University
The invention, the patent's abstract states, "provides three BCAS2 related nucleotide sequences … [as well as] a composition comprising a nucleotide sequence of small interfering RNA of BCAS2 gene."
It further provides "a method for treating p53 containing cancer comprising administrating a subject with an effective amount of the said composition," the abstract adds.
Title: RNAi Inhibition of Alpha-ENaC Expression
Patent Number: 7,718,632
Filed: June 16, 2008
Lead Inventor: Gino Van Heeke, Novartis
"The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the down-regulation of alpha-ENaC expression by chemically modified oligonucleotides," the patent's abstract states.
Title: Use of a Galectin-1-Targeted RNAi-Based Approach for the Treatment of Cancer
Application Number: 20100120891
Filed: March 9, 2006 PCT Filed: March 9, 2006
Lead Inventor: Isabelle Camby, Universite libre de Bruxelles
The invention, the patent application's abstract states, "relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing [certain pre-defined sequences] … and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer, and non-Hodgkin's lymphoma."
The invention also relates to "compositions and methods for treating and for delaying the progression of cancer … for reducing the migration of tumor cells … and/or for enhancing the efficacy of cancer therapies for the treatment of cancer [including] … chemotherapy, radiation therapy, immunotherapy, and/or gene therapy."
Title: Compositions and Methods for Inhibiting Expression of Transthyretin
Application Number: 20100120893
Filed: Oct. 20, 2009
Lead Inventor: Dinah Sah, Alnylam Pharmaceuticals
"The invention relates to a double-stranded ribonucleic acid targeting a transthyretin gene and methods of using the dsRNA to inhibit expression of TTR," according to the patent application's abstract.
Title: RNA Interference-Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase Gene Expression Using Short Interfering Nucleic Acid
Application Number: 20100120895
Filed: May 2, 2008 PCT Filed: May 2, 2008
Lead Inventor: India Vasant Jadhav, Sirna Therapeutics (Merck)
The invention, the patent application's abstract states, "relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of cyclic nucleotide type 4 phosphodiesterase gene expression and/or activity, including PDE4B1, PDE4B2, and PDE4B3 gene expression and/or activity."
The invention is also "directed to compounds, compositions, and methods relating to traits, diseases, and conditions that respond to the modulation of expression and/or activity of genes involved in cyclic nucleotide type 4 phosphodiesterase gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases, and conditions, including but not limited to IL-6, IL-7, IL-8, IL-15, TNF-alpha, and matrix metalloproteinases such as MMP-I, MMP-2, MMP-3, MMP-9, and MMP-12," the abstract adds.
"Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules … capable of mediating RNA interference against cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle formulations of such small nucleic acid molecules."
The invention further relates to small nucleic acid molecules … that can inhibit the function of endogenous RNA molecules or RNAi pathway components … or that can inhibit the function of RISC to modulate PDE4B gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs," it states. "Such small nucleic acid molecules are useful, for example, in providing compositions to prevent, inhibit, or reduce inflammatory, respiratory, and autoimmune diseases, traits, and conditions, and/or other disease states associated with PDE4B gene expression or activity in a subject or organism."
Title: microRNA Expression Signature for Predicting Survival and Metastases in Hepatocellular Carcinoma
Application Number: 20100120898
Filed: Nov. 1, 2007 PCT Filed: Nov. 1, 2007
Lead Inventor: Carlo Croce, Ohio State University
The patent application, its abstract states, claims "methods and compositions for the diagnosis, prognosis, and treatment of hepatocellular carcinoma," as well as methods of "identifying anti-HCC agents."
Title: Methods and Sequences to Preferentially Suppress Expression of Mutated Huntingtin
Application Number: 20100120900
Filed: Sept. 15, 2009
Lead Inventor: Paul van Bilsen, Medtronic
The patent application, its abstract states, claims "methods and sequences to preferentially suppress the expression of the mutated huntingtin protein over-expression. … Also [claimed] are methods comprising screening an individual for the heterozygous presence of one or more single nucleotide polymorphisms within the individual's Huntington's genes; administering nucleic acid molecules comprising nucleotide sequences that preferentially suppress the expression of amino acid sequences encoding for mutated huntingtin over-suppressing the expression of amino acid sequences encoding for normal [huntingtin] by targeting an area of a Huntington's disease gene that is heterozygous for the presence of one or more single nucleotide polymorphisms."
Title: Environment-Responding siRNA Carrier Using Disulfide Cross-Linked Polymeric Micelle
Application Number: 20100121043
Filed: Nov. 22, 2007 PCT Filed: Nov. 22, 2007
Lead Inventor: Kazunori Kataoka, University of Tokyo
The invention, the patent application's abstract states, comprises an "siRNA-encapsulating polymeric micelle complex having high monodispersibility and structural stability, and [which is] excellent in … transporting siRNA into a cell. Further disclosed are a nucleic acid-delivery device, a nucleic acid-delivery kit, a pharmaceutical composition, and a gene therapy agent, each of which uses the complex. The polyion complex is characterized by … a block copolymer composed of a polyethylene glycol moiety and a polycation moiety having a thiol group as a side chain at the terminus, [as well as an] siRNA."